Riskpilot← Back to searchSign inGet full accessAKTIESELSKABET AF 1. JUNI 2011 I
A/SActiveCVR 33751540Philip Heymans Alle 3Manufacture of pharmaceutical preparations · NACE 2120Est. 2011— employees
Revenue 2025
—
EBITDA margin
—
-4% vs 2024
Equity ratio
88.5%
Financial strength
Net profit 2025
DKK -2K
+73% vs 2024
| Revenue | — | — |
| EBITDA | DKK -17K | -4% |
| Net profit | DKK -2K | +73% |
| Total assets | DKK 285K | +5% |
| Equity | DKK 252K | -1% |
| Employees | — | — |
Legal name
AKTIESELSKABET AF 1. JUNI 2011 I
CVR number
33751540
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
30. maj 2011
Share capital
DKK 500.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør eller i forening med et andet bestyrelsesmedlem.
Company purpose
Selskabets formål er at drive forskning, handel, fabrikation og dermed beslægtet virksomhed primært inden for medicinal-branchen.
Address
Philip Heymans Alle 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -35 | -12 | -13 | -13 | -13 | -15 | -15 | -15 | -15 | -15 | -14 | -28 | -17 | -17 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -35 | -12 | -13 | -13 | -13 | -15 | -15 | -15 | -15 | -15 | -14 | -28 | -17 | -17 |
| Net financials | -0 | -32 | 0 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | 0 | 8 | 8 | 4 |
| Profit before tax | -35 | -45 | -13 | -15 | -15 | -17 | -17 | -17 | -17 | -17 | -14 | -21 | -8 | -13 |
| Tax | -9 | -3 | -3 | -3 | -3 | 10 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -11 |
| Net profit | -26 | -42 | -10 | -11 | -12 | -28 | -17 | -17 | -17 | -17 | -14 | -21 | -8 | -2 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 467 | 438 | 428 | 417 | 404 | 379 | 362 | 359 | 328 | 311 | 298 | 291 | 271 | 285 |
| Equity | 467 | 425 | 415 | 404 | 392 | 364 | 348 | 330 | 314 | 297 | 283 | 262 | 254 | 252 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 13 | 13 | 13 | 13 | 15 | 15 | 29 | 15 | 15 | 15 | 29 | 17 | 33 |
| Total debt | 0 | 13 | 13 | 13 | 13 | 15 | 15 | 29 | 15 | 15 | 15 | 29 | 17 | 33 |
EBITDA margin
-1725000.0%
This company
15.8%
Market median
-10917822% vs market
20122025
Equity ratio
88.5%
This company
38.2%
Market median
+132% vs market
20122025
Return on equity
-0.9%
This company
18.4%
Market median
-105% vs market
20122025
Net profit margin
-224900.0%
This company
8.1%
Market median
-2776643% vs market
20122025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122025
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CS Management | Management | 2011 | — | — |
HJ Management | Management | 2018 | — | — |
OL Management | Management | 2011 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2011 | — | — | |
| Chairman | 2014 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2011 | — | — | |
| Chairman | 2011 | — | — | |
| Chairman | 2011 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BAVARIAN NORDIC A/S | Company | 100.0% | 100.0% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Arbejdsmarkedets Tillægspension
AKTIESELSKABET AF 1. JUNI 2011 I Board members of AKTIESELSKABET AF 1. JUNI 2011 I also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Caroline Sundorph Pontoppidan | Management | 0 companies |
| Henrik Juuel | Management | 0 companies |
| Ole Larsen | Management | 0 companies |
| Henrik Møgelmose | Board of Directors | 0 companies |
| Paul John Chaplin | Chairman | 0 companies |
| Christian Boje Vilstrup | Board of Directors | 0 companies |
| Morten Max Rasmussen | Board of Directors | 0 companies |
| Michael Egede Budtz | Chairman | 0 companies |
| Anders Hedegaard | Chairman | 0 companies |
| Paul John Chaplin | Chairman | 0 companies |